We reported previously that docosahexaenoic acid (22:6)-containing phosphatidylcholine (PC), but not oleic acid-containing PC nor 22:6-containing phosphatidylethanolamine, is toxic to tumor cells in vitro. To test whether other polyunsaturated fatty acids share 22:6's cytotoxic activity, we treated cultured T27A murine leukemia cells with PC liposomes composed of stearic acid in the sn-1 position and alpha-linolenic acid (alpha-18:3), arachidonic acid (20:4), or eicosapentaenoic acid (20:5) in the sn-2 position. PC containing 22:6 in both positions was also tested. Following treatment, the cells were monitored for fatty acid composition, liposome uptake and viability. Here we demonstrate that cytotoxicity is unique to 22:6-containing PCs and is not shared by PCs with other polyunsaturated omega-3 and omega-6 fatty acids. Because PCs with fatty acids other than 22:6 were taken up by cells but did not kill the cells, we propose that 22:6-containing PCs incorporated into cellular membranes produce unique changes in the membrane structure incompatible with cell survival. PC liposomes containing 22:6 are potential drug delivery vehicles that may, by virtue of their cytotoxicity, serve concomitantly as adjunct cancer therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0304-3835(98)00163-3DOI Listing

Publication Analysis

Top Keywords

fatty acids
16
docosahexaenoic acid
8
omega-3 omega-6
8
omega-6 fatty
8
226-containing pcs
8
acid
6
fatty
5
cells
5
acid phosphatidylcholine
4
phosphatidylcholine mediates
4

Similar Publications

Current Perspectives of Diabetic Dyslipidemia and Treatment Modalities.

Curr Med Chem

January 2025

Cukurova University, Faculty of Medicine, Division of Endocrinology, Adana, Turkey.

Introduction: Diabetes mellitus is associated with an increased risk of atherosclerosis related to dyslipidemia. Although the terms hyperlipidemia and Diabetes Mellitus [DM] or diabetic dyslipidemia are interrelated to each other, these two conditions have some differences.

Aim: This study aimed to highlight possible mechanisms of hyperlipidemia and/or dyslipidemia in diabetic patients, which can be treated with available and newer hypolipidemic drugs.

View Article and Find Full Text PDF

Titanium dioxide nanoparticles (TiONPs) as an emerging pollutant in aquatic environments can interact with metals reducing or enhancing their toxicity in these environments. This study examined and compared the toxic effects of mercury ions (Hg ions) on immobilization percentage, fatty acid profile, and oxidative stress of nauplii, individually (Hg) and simultaneously in the presence of 0.10 mg.

View Article and Find Full Text PDF

Background Severe acute pancreatitis (SAP) manifests as a critical state marked by acute abdominal symptoms, often associated with intestinal barrier dysfunction, exacerbating SAP retroactively. Ganoderic acid A (GAA) demonstrates anti-inflammatory properties in various inflammatory disorders. Nonetheless, its potential therapeutic impact on SAP and the underlying mechanisms remain unexplored.

View Article and Find Full Text PDF

Pumpkin extract has been shown to alleviate hyperglycemic symptoms by improving glucose metabolism disorders. However, the specific active components responsible for its hypoglycemic effects and the underlying molecular mechanisms remain unclear. In this study, db/db mice underwent a 4-week dietary intervention with two pumpkin flours (PF1 and PF2), total dietary fiber (TDF), soluble dietary fiber (SDF), and insoluble dietary fiber (IDF), with acarbose serving as a positive control.

View Article and Find Full Text PDF

Prospects of elafibranor in treating alcohol-associated liver diseases.

World J Gastroenterol

January 2025

School of Basic Medicine, Qilu Medical University, Zibo 255300, Shandong Province, China.

Alcohol-related liver disease (ALD), which is induced by excessive alcohol consumption, is a leading cause of liver-related morbidity and mortality. ALD patients exhibit a spectrum of liver injuries, including hepatic steatosis, inflammation, and fibrosis, similar to symptoms of nonalcohol-associated liver diseases such as primary biliary cholangitis, metabolic dysfunction-associated steatotic liver disease, and nonalcoholic steatohepatitis. Elafibranor has been approved for the treatment of primary biliary cholangitis and has been shown to improve symptoms in both animal models and cell models of metabolic dysfunction-associated steatotic liver disease and nonalcoholic steatohepatitis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!